<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308567</url>
  </required_header>
  <id_info>
    <org_study_id>EFC11784</org_study_id>
    <secondary_id>2010-022064-12</secondary_id>
    <secondary_id>U1111-1117-8356</secondary_id>
    <nct_id>NCT01308567</nct_id>
  </id_info>
  <brief_title>Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer</brief_title>
  <acronym>FIRSTANA</acronym>
  <official_title>Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m^2 and at 20 mg/m^2 in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  To demonstrate the superiority of cabazitaxel plus prednisone at 25 mg/m^2 (Arm A) or 20
           mg/m^2 (Arm B) versus docetaxel plus prednisone (Arm C) in term of overall survival (OS)
           in participants with metastatic castration resistant prostate cancer (mCRPC) and not
           previously treated with chemotherapy.

      Secondary Objectives:

        -  To evaluate safety in the 3 treatment arms.

        -  To compare efficacy of cabazitaxel at 20 mg/m^2 and 25 mg/m^2 to docetaxel for:

             -  Progression Free Survival (PFS) (RECIST 1.1)

             -  Tumor progression free survival (RECIST 1.1)

             -  Tumor response in participants with measurable disease (RECIST 1.1),

             -  PSA response

             -  PSA-Progression free survival (PSA-PFS).

             -  Pain response in participants with stable pain at baseline

             -  Pain progression free survival

             -  Time to occurrence of any skeletal related events (SRE)

        -  To compare Health-Related Quality of Life (HRQL).

        -  To assess the pharmacokinetics and pharmacogenomics of cabazitaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants were treated until progressive disease, unacceptable toxicity, or participant's
      refusal of further study treatment. All participants were followed when on study treatment
      and after completion of study treatment during follow up period until death or the study
      cutoff date, whichever come first.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 5, 2011</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to death or study cut-off date, whichever was earlier (maximum duration: 51 months)</time_frame>
    <description>OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date if the participant's last contact was after the cut-off date. The study cut-off date for the final analysis of OS was the date when the 774th death had been observed. Analysis was performed by Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline up to tumor progression, PSA progression, pain progression or death (maximum duration: 51 months)</time_frame>
    <description>PFS: time interval between date of randomization to date of first occurrence of any of following events: tumor progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Prostate Specific Antigen (PSA) progression; pain progression or death due to any cause. Analysis was performed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression Free Survival</measure>
    <time_frame>Baseline up to tumor progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)</time_frame>
    <description>Time to tumor progression free survival was defined as the time interval between randomization and the date of first occurrence of tumor progression (assessed using RECIST version 1.1) or death, whichever was earlier. Analysis was performed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Objective Tumor Response</measure>
    <time_frame>Baseline up to DP or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)</time_frame>
    <description>Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Prostate Serum Antigen Progression Free Survival (PSA-PFS)</measure>
    <time_frame>Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier ((maximum duration: 51 months)</time_frame>
    <description>Time to PSA-PFS: time interval between date of randomization &amp; first occurrence of PSA progression/ death, whichever was earlier. PSA progression:1) In PSA responders(≥50% decline from baseline PSA of ≥10 ng/mL):increase of ≥25%(at least 2 ng/mL)over nadir value, confirmed by second PSA value at least 3 weeks later;2)In PSA non-responders(not achieved ≥50% decline from baseline PSA ≥10 ng/mL):increase of ≥25% (at least 2 ng/mL) over baseline value, confirmed by second PSA value at least 3 weeks later;3)In participants not eligible for PSA response(baseline PSA &lt;10 ng/mL):(a)in participants with baseline PSA&gt;0 ng/mL&amp;&lt;10 ng/mL: increase in PSA by 25% (at least 2 ng/mL) above baseline level, confirmed by second PSA value at least 3weeks apart;(b)in participants with baseline value=0ng/mL: a post baseline PSA value ≥2ng/mL.Early rise in PSA only indicated progression if it was associated with another sign of DP or if it continued beyond 12 weeks. Analysis performed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PSA Response</measure>
    <time_frame>Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)</time_frame>
    <description>PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pain Progression Free Survival (Pain PFS)</measure>
    <time_frame>Baseline until disease progression, death or study cut-off date (maximum duration: 51 months)</time_frame>
    <description>Time to pain PFS was defined as the time interval between date of randomization and the date of the first occurrence of pain progression or death, whichever was earlier. Pain progression was defined as an increase of ≥1 point in the median present pain intensity (PPI) score from the nadir confirmed by a second assessment at least 3 weeks later or ≥25 % increase in the mean analgesic score from baseline, due to cancer related pain confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pain Response</measure>
    <time_frame>Baseline until pain progression, death or study cut-off date (maximum duration: 51 months)</time_frame>
    <description>Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in analgesic score, or a ≥50% decrease in analgesic use from baseline mean analgesic score (only in participants with baseline mean analgesic score≥10) without increase in the pain. Either criterion was maintained for 2 consecutive evaluations at least 3 weeks apart. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal Related Events (SRE) Free Survival</measure>
    <time_frame>Baseline until occurrence of first SRE or death (maximum duration: 51 months)</time_frame>
    <description>SRE free survival was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SRE or death due to any cause, whichever was earlier. SRE were assessed by clinical evaluation. Occurrence of SRE was defined as: pathological fracture(s) and/or spinal cord compression; need for bone irradiation, including radioisotopes or bone surgery; and change of antineoplastic therapy (including introduction of bisphosphonates or denosumab in the setting of increased pain) to treat bone pain. Analysis was performed by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score as a Measure of Health Related Quality of Life (HRQoL)</measure>
    <time_frame>Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)</time_frame>
    <description>FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of HRQoL</measure>
    <time_frame>Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)</time_frame>
    <description>FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). Physical well being, functional well being, and prostate-specific concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1170</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel 25 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel 25 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabazitaxel 20 mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel 75 mg/m^2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel (XRP6258)</intervention_name>
    <description>Pharmaceutical form: Solution for injection; Route of administration: Intravenous</description>
    <arm_group_label>Cabazitaxel 25 mg/m^2</arm_group_label>
    <arm_group_label>Cabazitaxel 20 mg/m^2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel (XRP6976)</intervention_name>
    <description>Pharmaceutical form: Solution for injection'; Route of administration: Intravenous</description>
    <arm_group_label>Docetaxel 75 mg/m^2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Pharmaceutical form: Tablet; Route of administration: Oral</description>
    <arm_group_label>Cabazitaxel 25 mg/m^2</arm_group_label>
    <arm_group_label>Cabazitaxel 20 mg/m^2</arm_group_label>
    <arm_group_label>Docetaxel 75 mg/m^2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  I 01. Histologically- or cytologically-confirmed prostate adenocarcinoma.

          -  I 02. Metastatic disease.

          -  I 03. Progressive disease while receiving hormonal therapy or after surgical
             castration.

          -  I 04. Effective castration (serum testosterone levels ≤0.50 ng/mL) by orchiectomy
             and/or luteinizing hormone-releasing hormone (LHRH) agonists or antagonist with or
             without anti-androgens.

        Exclusion criteria:

          -  E 01. Prior chemotherapy for prostate cancer,

          -  E 02. Less than 28 days elapsed from prior treatment with estramustine, radiotherapy
             or surgery to the time of randomization. Participants on biphosphonates prior to study
             entry.

          -  E 03. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to &gt;30% of
             bone marrow.

          -  E 04. Adverse events (excluding alopecia and those listed in the specific exclusion
             criteria) from any prior anticancer therapy of grade &gt;1(National Cancer Institute
             Common Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization.

          -  E 05. Less than 18 years (or country's legal age of majority if the legal age is &gt;18
             years).

          -  E 06. Eastern Cooperative Oncology Group (ECOG) performance status &gt;2.

          -  E 07. History of brain metastases, uncontrolled spinal cord compression, or
             carcinomatous meningitis or new evidence of brain or leptomeningeal disease.

          -  E 08. Prior malignancy.

          -  E 09. Participation in another clinical trial and any concurrent treatment with any
             investigational drug within 30 days prior to randomization.

          -  E 10. Any of the following within 6 months prior to study enrollment: myocardial
             infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft,
             New York Heart Association (NYHA) class III or IV congestive heart failure, stroke or
             transient ischemic attack.

          -  E 11. Any of the following within 3 months prior to randomization: treatment resistant
             peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory
             bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled
             thromboembolic event.

          -  E 12. Acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease
             requiring antiretroviral treatment.

          -  E 13. Any severe acute or chronic medical condition which could impair the ability of
             the participant to participate to the study or interfere with interpretation of study
             results, or participants unable to comply with the study procedures.

          -  E 14. Absence of signed and dated Institutional Review Board (IRB)-approved
             participant informed consent form prior to enrollment into the study.

          -  E 15. Participants with reproductive potential who did not agree to use accepted and
             effective method of contraception during the study treatment period.

          -  E 16. History of hypersensitivity to docetaxel, or polysorbate 80.

          -  E 17. Inadequate organ and bone marrow function

          -  E 18. Contraindications to the use of corticosteroid treatment.

          -  E 19. Symptomatic peripheral neuropathy grade &gt;2 (National Cancer Institute Common
             Terminology Criteria [NCI CTCAE] v.4.03).

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840009</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840014</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840030</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840012</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840019</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840013</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840035</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840015</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840018</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840010</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840008</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840238</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840138</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840038</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840005</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840021</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840016</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840020</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840017</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840033</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840036</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840011</name>
      <address>
        <city>Washington</city>
        <state>North Carolina</state>
        <zip>27889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840026</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840023</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840032</name>
      <address>
        <city>Dunmore</city>
        <state>Pennsylvania</state>
        <zip>18512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840007</name>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <zip>02860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840037</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840028</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036016</name>
      <address>
        <city>Bankstown</city>
        <zip>2200</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036008</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036015</name>
      <address>
        <city>Coffs Harbour</city>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036001</name>
      <address>
        <city>Concord</city>
        <zip>2137</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036017</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036003</name>
      <address>
        <city>Herston</city>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036010</name>
      <address>
        <city>Hornsby</city>
        <zip>2077</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036012</name>
      <address>
        <city>Kurralta Park</city>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036002</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036009</name>
      <address>
        <city>South Brisbane</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036011</name>
      <address>
        <city>Subiaco</city>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 036013</name>
      <address>
        <city>Wodonga</city>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 112001</name>
      <address>
        <city>Minsk</city>
        <zip>220013</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 112002</name>
      <address>
        <city>Minsk</city>
        <zip>223040</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 112004</name>
      <address>
        <city>Vitebsk</city>
        <zip>210603</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076006</name>
      <address>
        <city>Passo Fundo</city>
        <zip>99010-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076001</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076002</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076004</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20230-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076009</name>
      <address>
        <city>Sao Jose Do Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076005</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076003</name>
      <address>
        <city>Uberlandia</city>
        <zip>38408 150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124002</name>
      <address>
        <city>London</city>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124007</name>
      <address>
        <city>Mississauga</city>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124005</name>
      <address>
        <city>Moncton</city>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124003</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124004</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124006</name>
      <address>
        <city>Toronto</city>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156005</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156002</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156003</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156004</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203002</name>
      <address>
        <city>Brno</city>
        <zip>65653</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203003</name>
      <address>
        <city>Novy Jicin</city>
        <zip>74101</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203001</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203004</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208002</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208001</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208003</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208004</name>
      <address>
        <city>Ålborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246002</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246001</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 246003</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250010</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250002</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250006</name>
      <address>
        <city>Caen Cedex 05</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250005</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250003</name>
      <address>
        <city>Paris Cedex 05</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250004</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250007</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250008</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250009</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276003</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276005</name>
      <address>
        <city>Berlin</city>
        <zip>14197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276004</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276002</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276006</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 376004</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 376003</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 376002</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380001</name>
      <address>
        <city>Arezzo</city>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380004</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380003</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380005</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380002</name>
      <address>
        <city>Trento</city>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Bunkyo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392003</name>
      <address>
        <city>Chiba-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392006</name>
      <address>
        <city>Kashiwa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392005</name>
      <address>
        <city>Koto-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392002</name>
      <address>
        <city>Osaka Sayama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392004</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484007</name>
      <address>
        <city>Acapulco</city>
        <zip>39670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484008</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484003</name>
      <address>
        <city>D.f.</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484004</name>
      <address>
        <city>Guadalajara</city>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484009</name>
      <address>
        <city>Merida</city>
        <zip>97134</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484005</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484002</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484006</name>
      <address>
        <city>Zapopan</city>
        <zip>45040</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 604006</name>
      <address>
        <city>Lima</city>
        <zip>027</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 604001</name>
      <address>
        <city>Lima</city>
        <zip>041</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 604005</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 604002</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616002</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616001</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616003</name>
      <address>
        <city>Koscierzyna</city>
        <zip>83-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616005</name>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616004</name>
      <address>
        <city>Poznan</city>
        <zip>61-485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 620003</name>
      <address>
        <city>Coimbra</city>
        <zip>3049</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 620005</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 620004</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 620001</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 620002</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642004</name>
      <address>
        <city>Baia Mare</city>
        <zip>430031</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642008</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642005</name>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642002</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642003</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642007</name>
      <address>
        <city>Hunedoara</city>
        <zip>331057</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643004</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643008</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643003</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643002</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643007</name>
      <address>
        <city>Ryazan</city>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643005</name>
      <address>
        <city>St-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643001</name>
      <address>
        <city>Tomsk</city>
        <zip>634028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 643006</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724001</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724007</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724002</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724003</name>
      <address>
        <city>Hospitalet De Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724005</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724004</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724006</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752003</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752002</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 752001</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158004</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158002</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158001</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158003</name>
      <address>
        <city>Tao-Yuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792002</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792001</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804009</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804004</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804010</name>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804006</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804003</name>
      <address>
        <city>Kharkov</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804002</name>
      <address>
        <city>Kyiv</city>
        <zip>01133</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804001</name>
      <address>
        <city>Kyiv</city>
        <zip>1601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804007</name>
      <address>
        <city>Lutsk</city>
        <zip>43018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804005</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 804008</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69040</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belarus</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <results_first_submitted>September 8, 2016</results_first_submitted>
  <results_first_submitted_qc>January 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2017</results_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 159 centers in 25 countries. A total of 1510 participants were screened between 17 May 2011 and 09 September 2015 of whom 1168 participants were randomized and 342 were considered as screen failures.</recruitment_details>
      <pre_assignment_details>A total of 1168 participants were randomized in this study. Of these, 21 participants were randomized but were not treated. These participants were included in intent-to-treat (ITT) population and not in safety population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel 75 mg/m^2</title>
          <description>Docetaxel (TXT) 75 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant’s refusal.</description>
        </group>
        <group group_id="P2">
          <title>Cabazitaxel 20 mg/m^2</title>
          <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21–day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
        </group>
        <group group_id="P3">
          <title>Cabazitaxel 25 mg/m^2</title>
          <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="391">Randomized</participants>
                <participants group_id="P2" count="389">Randomized</participants>
                <participants group_id="P3" count="388">Randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="388">For 1 participant, actual treatment received was Cabazitaxel 25 mg/m^2.</participants>
                <participants group_id="P2" count="382">For 15 participants, actual treatment received was Cabazitaxel 25 mg/m^2.</participants>
                <participants group_id="P3" count="377">For 2 participants, actual treatment received was Cabazitaxel 20 mg/m^2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ongoing Treatment at Data Cut-off</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="389">Completed participants included those who withdrew treatment consent but were followed for survival.</participants>
                <participants group_id="P2" count="385">Completed participants included those who withdrew treatment consent but were followed for survival.</participants>
                <participants group_id="P3" count="384">Completed participants included those who withdrew treatment consent but were followed for survival.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel 75 mg/m^2</title>
          <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
        </group>
        <group group_id="B2">
          <title>Cabazitaxel 20 mg/m^2</title>
          <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21–day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
        </group>
        <group group_id="B3">
          <title>Cabazitaxel 25 mg/m^2</title>
          <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="391"/>
            <count group_id="B2" value="389"/>
            <count group_id="B3" value="388"/>
            <count group_id="B4" value="1168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="182"/>
                    <measurement group_id="B4" value="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="391"/>
                    <measurement group_id="B2" value="389"/>
                    <measurement group_id="B3" value="388"/>
                    <measurement group_id="B4" value="1168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date if the participant’s last contact was after the cut-off date. The study cut-off date for the final analysis of OS was the date when the 774th death had been observed. Analysis was performed by Kaplan-Meier method.</description>
        <time_frame>Baseline up to death or study cut-off date, whichever was earlier (maximum duration: 51 months)</time_frame>
        <population>ITT population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel 20 mg/m^2</title>
            <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 –day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel 25 mg/m^2</title>
            <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date if the participant’s last contact was after the cut-off date. The study cut-off date for the final analysis of OS was the date when the 774th death had been observed. Analysis was performed by Kaplan-Meier method.</description>
          <population>ITT population included all randomized participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" lower_limit="22.18" upper_limit="27.60"/>
                    <measurement group_id="O2" value="24.5" lower_limit="21.75" upper_limit="27.20"/>
                    <measurement group_id="O3" value="25.2" lower_limit="22.90" upper_limit="26.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by Eastern Cooperative Oncology Group performance status (ECOG PS) score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7574</p_value>
            <p_value_desc>P-value from two-sided stratified log-rank test, stratified for ECOG PS score at baseline, measurable disease at baseline and region with commercial availability of cabazitaxel at time of randomization. Threshold for statistical significance = 0.0479</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.975</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.819</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>Cabazitaxel 25 mg/m^2 vs Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9967</p_value>
            <p_value_desc>P-value from two-sided stratified log-rank test, stratified for ECOG PS score at baseline, measurable disease at baseline and region with commercial availability of cabazitaxel at time of randomization. Threshold for statistical significance = 0.0479</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.009</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.197</ci_upper_limit>
            <estimate_desc>Cabazitaxel 20 mg/m^2 vs Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS: time interval between date of randomization to date of first occurrence of any of following events: tumor progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Prostate Specific Antigen (PSA) progression; pain progression or death due to any cause. Analysis was performed by Kaplan-Meier method.</description>
        <time_frame>Baseline up to tumor progression, PSA progression, pain progression or death (maximum duration: 51 months)</time_frame>
        <population>ITT population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel 20 mg/m^2</title>
            <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 –day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel 25 mg/m^2</title>
            <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS: time interval between date of randomization to date of first occurrence of any of following events: tumor progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Prostate Specific Antigen (PSA) progression; pain progression or death due to any cause. Analysis was performed by Kaplan-Meier method.</description>
          <population>ITT population included all randomized participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.86" upper_limit="5.78"/>
                    <measurement group_id="O2" value="4.4" lower_limit="3.91" upper_limit="5.09"/>
                    <measurement group_id="O3" value="5.1" lower_limit="4.60" upper_limit="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.989</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.849</ci_lower_limit>
            <ci_upper_limit>1.152</ci_upper_limit>
            <estimate_desc>Cabazitaxel 25 mg/m^2 vs Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.063</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.913</ci_lower_limit>
            <ci_upper_limit>1.236</ci_upper_limit>
            <estimate_desc>Cabazitaxel 20 mg/m^2 vs Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Progression Free Survival</title>
        <description>Time to tumor progression free survival was defined as the time interval between randomization and the date of first occurrence of tumor progression (assessed using RECIST version 1.1) or death, whichever was earlier. Analysis was performed by Kaplan-Meier method.</description>
        <time_frame>Baseline up to tumor progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)</time_frame>
        <population>ITT population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel 20 mg/m^2</title>
            <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 –day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel 25 mg/m^2</title>
            <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression Free Survival</title>
          <description>Time to tumor progression free survival was defined as the time interval between randomization and the date of first occurrence of tumor progression (assessed using RECIST version 1.1) or death, whichever was earlier. Analysis was performed by Kaplan-Meier method.</description>
          <population>ITT population included all randomized participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="11.30" upper_limit="13.77"/>
                    <measurement group_id="O2" value="13.4" lower_limit="11.37" upper_limit="14.75"/>
                    <measurement group_id="O3" value="13.1" lower_limit="11.66" upper_limit="14.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.958</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.785</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>Cabazitaxel 25 mg/m^2 vs Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.916</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.118</ci_upper_limit>
            <estimate_desc>Cabazitaxel 20 mg/m^2 vs Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Overall Objective Tumor Response</title>
        <description>Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.</description>
        <time_frame>Baseline up to DP or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)</time_frame>
        <population>Analysis was performed on ITT population. Number of participants analyzed=participants with measurable disease at baseline and at least one valid post-baseline value analyzed for specified outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel 20 mg/m^2</title>
            <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 –day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel 25 mg/m^2</title>
            <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Overall Objective Tumor Response</title>
          <description>Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.</description>
          <population>Analysis was performed on ITT population. Number of participants analyzed=participants with measurable disease at baseline and at least one valid post-baseline value analyzed for specified outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" lower_limit="24.0" upper_limit="37.7"/>
                    <measurement group_id="O2" value="32.4" lower_limit="25.8" upper_limit="39.1"/>
                    <measurement group_id="O3" value="41.6" lower_limit="34.3" upper_limit="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Prostate Serum Antigen Progression Free Survival (PSA-PFS)</title>
        <description>Time to PSA-PFS: time interval between date of randomization &amp; first occurrence of PSA progression/ death, whichever was earlier. PSA progression:1) In PSA responders(≥50% decline from baseline PSA of ≥10 ng/mL):increase of ≥25%(at least 2 ng/mL)over nadir value, confirmed by second PSA value at least 3 weeks later;2)In PSA non-responders(not achieved ≥50% decline from baseline PSA ≥10 ng/mL):increase of ≥25% (at least 2 ng/mL) over baseline value, confirmed by second PSA value at least 3 weeks later;3)In participants not eligible for PSA response(baseline PSA &lt;10 ng/mL):(a)in participants with baseline PSA&gt;0 ng/mL&amp;&lt;10 ng/mL: increase in PSA by 25% (at least 2 ng/mL) above baseline level, confirmed by second PSA value at least 3weeks apart;(b)in participants with baseline value=0ng/mL: a post baseline PSA value ≥2ng/mL.Early rise in PSA only indicated progression if it was associated with another sign of DP or if it continued beyond 12 weeks. Analysis performed by Kaplan-Meier method.</description>
        <time_frame>Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier ((maximum duration: 51 months)</time_frame>
        <population>Analysis was performed on ITT population which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel 20 mg/m^2</title>
            <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 –day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel 25 mg/m^2</title>
            <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Prostate Serum Antigen Progression Free Survival (PSA-PFS)</title>
          <description>Time to PSA-PFS: time interval between date of randomization &amp; first occurrence of PSA progression/ death, whichever was earlier. PSA progression:1) In PSA responders(≥50% decline from baseline PSA of ≥10 ng/mL):increase of ≥25%(at least 2 ng/mL)over nadir value, confirmed by second PSA value at least 3 weeks later;2)In PSA non-responders(not achieved ≥50% decline from baseline PSA ≥10 ng/mL):increase of ≥25% (at least 2 ng/mL) over baseline value, confirmed by second PSA value at least 3 weeks later;3)In participants not eligible for PSA response(baseline PSA &lt;10 ng/mL):(a)in participants with baseline PSA&gt;0 ng/mL&amp;&lt;10 ng/mL: increase in PSA by 25% (at least 2 ng/mL) above baseline level, confirmed by second PSA value at least 3weeks apart;(b)in participants with baseline value=0ng/mL: a post baseline PSA value ≥2ng/mL.Early rise in PSA only indicated progression if it was associated with another sign of DP or if it continued beyond 12 weeks. Analysis performed by Kaplan-Meier method.</description>
          <population>Analysis was performed on ITT population which included all randomized participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="7.66" upper_limit="9.20"/>
                    <measurement group_id="O2" value="8.2" lower_limit="7.43" upper_limit="8.90"/>
                    <measurement group_id="O3" value="9.2" lower_limit="8.44" upper_limit="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.948</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>1.123</ci_upper_limit>
            <estimate_desc>Cabazitaxel 25 mg/m^2 vs Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was estimated using a COX Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.886</ci_lower_limit>
            <ci_upper_limit>1.238</ci_upper_limit>
            <estimate_desc>Cabazitaxel 20 mg/m^2 vs Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PSA Response</title>
        <description>PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.</description>
        <time_frame>Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)</time_frame>
        <population>Analysis was performed on ITT population. Number of participants analyzed=participants with PSA value ≥10 ng/mL at baseline and at least one valid post-baseline value for specified outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel 20 mg/m^2</title>
            <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 –day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel 25 mg/m^2</title>
            <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PSA Response</title>
          <description>PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.</description>
          <population>Analysis was performed on ITT population. Number of participants analyzed=participants with PSA value ≥10 ng/mL at baseline and at least one valid post-baseline value for specified outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="63.5" upper_limit="73.2"/>
                    <measurement group_id="O2" value="60.7" lower_limit="55.5" upper_limit="65.8"/>
                    <measurement group_id="O3" value="68.7" lower_limit="63.8" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Pain Progression Free Survival (Pain PFS)</title>
        <description>Time to pain PFS was defined as the time interval between date of randomization and the date of the first occurrence of pain progression or death, whichever was earlier. Pain progression was defined as an increase of ≥1 point in the median present pain intensity (PPI) score from the nadir confirmed by a second assessment at least 3 weeks later or ≥25 % increase in the mean analgesic score from baseline, due to cancer related pain confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.</description>
        <time_frame>Baseline until disease progression, death or study cut-off date (maximum duration: 51 months)</time_frame>
        <population>Analysis was performed on ITT population which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel 20 mg/m^2</title>
            <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 –day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel 25 mg/m^2</title>
            <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pain Progression Free Survival (Pain PFS)</title>
          <description>Time to pain PFS was defined as the time interval between date of randomization and the date of the first occurrence of pain progression or death, whichever was earlier. Pain progression was defined as an increase of ≥1 point in the median present pain intensity (PPI) score from the nadir confirmed by a second assessment at least 3 weeks later or ≥25 % increase in the mean analgesic score from baseline, due to cancer related pain confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.</description>
          <population>Analysis was performed on ITT population which included all randomized participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="8.28" upper_limit="11.76"/>
                    <measurement group_id="O2" value="8.0" lower_limit="6.90" upper_limit="9.66"/>
                    <measurement group_id="O3" value="7.3" lower_limit="6.44" upper_limit="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.189</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.986</ci_lower_limit>
            <ci_upper_limit>1.434</ci_upper_limit>
            <estimate_desc>Cabazitaxel 25 mg/m^2 vs Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.189</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.985</ci_lower_limit>
            <ci_upper_limit>1.435</ci_upper_limit>
            <estimate_desc>Cabazitaxel 20 mg/m^2 vs Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pain Response</title>
        <description>Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in analgesic score, or a ≥50% decrease in analgesic use from baseline mean analgesic score (only in participants with baseline mean analgesic score≥10) without increase in the pain. Either criterion was maintained for 2 consecutive evaluations at least 3 weeks apart. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points.</description>
        <time_frame>Baseline until pain progression, death or study cut-off date (maximum duration: 51 months)</time_frame>
        <population>Analysis was performed on ITT population. Number of participants analyzed=participants with pain score with median PPI ≥2 and/or mean analgesic score≥10 points at baseline and at least one valid post-baseline value for specified outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel 20 mg/m^2</title>
            <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 –day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel 25 mg/m^2</title>
            <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pain Response</title>
          <description>Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in analgesic score, or a ≥50% decrease in analgesic use from baseline mean analgesic score (only in participants with baseline mean analgesic score≥10) without increase in the pain. Either criterion was maintained for 2 consecutive evaluations at least 3 weeks apart. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points.</description>
          <population>Analysis was performed on ITT population. Number of participants analyzed=participants with pain score with median PPI ≥2 and/or mean analgesic score≥10 points at baseline and at least one valid post-baseline value for specified outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" lower_limit="30.0" upper_limit="51.4"/>
                    <measurement group_id="O2" value="42.4" lower_limit="32.7" upper_limit="52.2"/>
                    <measurement group_id="O3" value="39.4" lower_limit="30.0" upper_limit="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skeletal Related Events (SRE) Free Survival</title>
        <description>SRE free survival was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SRE or death due to any cause, whichever was earlier. SRE were assessed by clinical evaluation. Occurrence of SRE was defined as: pathological fracture(s) and/or spinal cord compression; need for bone irradiation, including radioisotopes or bone surgery; and change of antineoplastic therapy (including introduction of bisphosphonates or denosumab in the setting of increased pain) to treat bone pain. Analysis was performed by Kaplan-Meier method.</description>
        <time_frame>Baseline until occurrence of first SRE or death (maximum duration: 51 months)</time_frame>
        <population>Analysis was performed on ITT population which included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel 20 mg/m^2</title>
            <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 –day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel 25 mg/m^2</title>
            <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
        </group_list>
        <measure>
          <title>Skeletal Related Events (SRE) Free Survival</title>
          <description>SRE free survival was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SRE or death due to any cause, whichever was earlier. SRE were assessed by clinical evaluation. Occurrence of SRE was defined as: pathological fracture(s) and/or spinal cord compression; need for bone irradiation, including radioisotopes or bone surgery; and change of antineoplastic therapy (including introduction of bisphosphonates or denosumab in the setting of increased pain) to treat bone pain. Analysis was performed by Kaplan-Meier method.</description>
          <population>Analysis was performed on ITT population which included all randomized participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="15.24" upper_limit="22.44"/>
                    <measurement group_id="O2" value="19.2" lower_limit="15.21" upper_limit="24.61"/>
                    <measurement group_id="O3" value="17.1" lower_limit="14.59" upper_limit="20.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was estimated using a COX Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.121</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.886</ci_lower_limit>
            <ci_upper_limit>1.417</ci_upper_limit>
            <estimate_desc>Cabazitaxel 25 mg/m^2 vs Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio was estimated using a COX Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.014</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.798</ci_lower_limit>
            <ci_upper_limit>1.288</ci_upper_limit>
            <estimate_desc>Cabazitaxel 20 mg/m^2 vs Docetaxel 75 mg/m^2</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score as a Measure of Health Related Quality of Life (HRQoL)</title>
        <description>FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms.</description>
        <time_frame>Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)</time_frame>
        <population>Analysis was performed on FACT-P population that included all participants with evaluable individual FACT-P subscale score at baseline and post-baseline on at least 1 of the subscale domains.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel 20 mg/m^2</title>
            <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 –day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel 25 mg/m^2</title>
            <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score as a Measure of Health Related Quality of Life (HRQoL)</title>
          <description>FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms.</description>
          <population>Analysis was performed on FACT-P population that included all participants with evaluable individual FACT-P subscale score at baseline and post-baseline on at least 1 of the subscale domains.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="370"/>
                <count group_id="O3" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Cycle 1 (n=333, 323, 321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="1.3" upper_limit="7.05"/>
                    <measurement group_id="O2" value="7.66" lower_limit="4.79" upper_limit="10.53"/>
                    <measurement group_id="O3" value="6.93" lower_limit="3.97" upper_limit="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 2 (n=339, 339, 323)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" lower_limit="2.46" upper_limit="8.2"/>
                    <measurement group_id="O2" value="7.15" lower_limit="4.28" upper_limit="10.01"/>
                    <measurement group_id="O3" value="5.28" lower_limit="2.32" upper_limit="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 3 (n=330, 332, 316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" lower_limit="2.06" upper_limit="7.82"/>
                    <measurement group_id="O2" value="6.79" lower_limit="3.93" upper_limit="9.66"/>
                    <measurement group_id="O3" value="4.61" lower_limit="1.64" upper_limit="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 4 (n=316, 323, 302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" lower_limit="1.17" upper_limit="6.96"/>
                    <measurement group_id="O2" value="5.22" lower_limit="2.35" upper_limit="8.09"/>
                    <measurement group_id="O3" value="4.01" lower_limit="1.03" upper_limit="6.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 5 (n=293, 290, 283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.36" lower_limit="1.44" upper_limit="7.27"/>
                    <measurement group_id="O2" value="5.16" lower_limit="2.26" upper_limit="8.06"/>
                    <measurement group_id="O3" value="4.09" lower_limit="1.09" upper_limit="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 6 (n=272, 267, 262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" lower_limit="0.53" upper_limit="6.39"/>
                    <measurement group_id="O2" value="3.8" lower_limit="0.88" upper_limit="6.73"/>
                    <measurement group_id="O3" value="3.37" lower_limit="0.35" upper_limit="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 7 (n=244, 246, 241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" lower_limit="0.2" upper_limit="6.12"/>
                    <measurement group_id="O2" value="3.66" lower_limit="0.71" upper_limit="6.61"/>
                    <measurement group_id="O3" value="3.42" lower_limit="0.38" upper_limit="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 8 (n=228, 222, 225)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" lower_limit="-0.37" upper_limit="5.59"/>
                    <measurement group_id="O2" value="2.71" lower_limit="-0.27" upper_limit="5.68"/>
                    <measurement group_id="O3" value="1.67" lower_limit="-1.39" upper_limit="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 9 (n=174, 196, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="-0.87" upper_limit="5.27"/>
                    <measurement group_id="O2" value="2.67" lower_limit="-0.35" upper_limit="5.68"/>
                    <measurement group_id="O3" value="1.89" lower_limit="-1.22" upper_limit="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 10 (n=149, 164, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" lower_limit="-1.05" upper_limit="5.21"/>
                    <measurement group_id="O2" value="2.09" lower_limit="-0.99" upper_limit="5.18"/>
                    <measurement group_id="O3" value="1.84" lower_limit="-1.32" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 11 (n=101, 115, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="-3.18" upper_limit="3.47"/>
                    <measurement group_id="O2" value="3.35" lower_limit="0.1" upper_limit="6.6"/>
                    <measurement group_id="O3" value="2.68" lower_limit="-0.67" upper_limit="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 12 (n=83, 98, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="-2.94" upper_limit="3.97"/>
                    <measurement group_id="O2" value="3.95" lower_limit="0.61" upper_limit="7.29"/>
                    <measurement group_id="O3" value="0.63" lower_limit="-2.78" upper_limit="4.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 13 (n=58, 85, 80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" lower_limit="-1.94" upper_limit="5.53"/>
                    <measurement group_id="O2" value="2.48" lower_limit="-0.95" upper_limit="5.91"/>
                    <measurement group_id="O3" value="0.55" lower_limit="-3" upper_limit="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 14 (n=55, 78, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" lower_limit="-5.56" upper_limit="2"/>
                    <measurement group_id="O2" value="2.2" lower_limit="-1.29" upper_limit="5.69"/>
                    <measurement group_id="O3" value="-0.42" lower_limit="-4.06" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 15 (n=44, 71, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.49" lower_limit="-7.5" upper_limit="0.51"/>
                    <measurement group_id="O2" value="1.74" lower_limit="-1.82" upper_limit="5.3"/>
                    <measurement group_id="O3" value="1.22" lower_limit="-2.51" upper_limit="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 16 (n=42, 58, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.83" lower_limit="-7.89" upper_limit="0.23"/>
                    <measurement group_id="O2" value="1.62" lower_limit="-2.11" upper_limit="5.35"/>
                    <measurement group_id="O3" value="0.5" lower_limit="-3.3" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up 1 (n=176, 185, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" lower_limit="-4.15" upper_limit="1.99"/>
                    <measurement group_id="O2" value="-1.45" lower_limit="-4.48" upper_limit="1.59"/>
                    <measurement group_id="O3" value="-1.82" lower_limit="-4.97" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up 2 (n=145, 129, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-3.16" upper_limit="3.13"/>
                    <measurement group_id="O2" value="-1.98" lower_limit="-5.17" upper_limit="1.21"/>
                    <measurement group_id="O3" value="-1.78" lower_limit="-5.04" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up 3 (n=110, 103, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" lower_limit="-3.83" upper_limit="2.74"/>
                    <measurement group_id="O2" value="-2.16" lower_limit="-5.47" upper_limit="1.14"/>
                    <measurement group_id="O3" value="-2.68" lower_limit="-6.08" upper_limit="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up 4 (n=87, 73, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" lower_limit="-4.61" upper_limit="2.23"/>
                    <measurement group_id="O2" value="-3.64" lower_limit="-7.18" upper_limit="-0.1"/>
                    <measurement group_id="O3" value="-1.7" lower_limit="-5.25" upper_limit="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up 5 (n=72, 63, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.05" lower_limit="-5.61" upper_limit="1.51"/>
                    <measurement group_id="O2" value="-6.73" lower_limit="-10.39" upper_limit="-3.06"/>
                    <measurement group_id="O3" value="-0.6" lower_limit="-4.18" upper_limit="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up 6 (n=58, 46, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" lower_limit="-4.92" upper_limit="2.58"/>
                    <measurement group_id="O2" value="-5.36" lower_limit="-9.32" upper_limit="-1.4"/>
                    <measurement group_id="O3" value="-4.05" lower_limit="-7.87" upper_limit="-0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of HRQoL</title>
        <description>FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). Physical well being, functional well being, and prostate-specific concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.</description>
        <time_frame>Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)</time_frame>
        <population>Analysis was performed on FACT-P population that included all participants with evaluable individual FACT-P subscale score at baseline and post-baseline on at least 1 of the subscale domains.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel 75 mg/m^2</title>
            <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O2">
            <title>Cabazitaxel 20 mg/m^2</title>
            <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 –day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
          <group group_id="O3">
            <title>Cabazitaxel 25 mg/m^2</title>
            <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant’s refusal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of HRQoL</title>
          <description>FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). Physical well being, functional well being, and prostate-specific concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.</description>
          <population>Analysis was performed on FACT-P population that included all participants with evaluable individual FACT-P subscale score at baseline and post-baseline on at least 1 of the subscale domains.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="371"/>
                <count group_id="O3" value="361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Cycle 1 (n=331, 324, 318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" lower_limit="1.05" upper_limit="5.58"/>
                    <measurement group_id="O2" value="6.09" lower_limit="3.83" upper_limit="8.35"/>
                    <measurement group_id="O3" value="5.76" lower_limit="3.43" upper_limit="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 2 (n=334, 337, 318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.37" lower_limit="2.1" upper_limit="6.64"/>
                    <measurement group_id="O2" value="5.96" lower_limit="3.7" upper_limit="8.21"/>
                    <measurement group_id="O3" value="4.26" lower_limit="1.92" upper_limit="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 3 (n=325, 332, 314)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" lower_limit="2.04" upper_limit="6.58"/>
                    <measurement group_id="O2" value="5.28" lower_limit="3.02" upper_limit="7.53"/>
                    <measurement group_id="O3" value="3.65" lower_limit="1.31" upper_limit="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 4 (n=313, 321, 301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" lower_limit="1.11" upper_limit="5.67"/>
                    <measurement group_id="O2" value="4.1" lower_limit="1.83" upper_limit="6.36"/>
                    <measurement group_id="O3" value="3.2" lower_limit="0.85" upper_limit="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 5 (n=289, 285, 282)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" lower_limit="1.11" upper_limit="5.7"/>
                    <measurement group_id="O2" value="4.05" lower_limit="1.76" upper_limit="6.34"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.74" upper_limit="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 6 (n=270, 264, 260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" lower_limit="0.45" upper_limit="5.07"/>
                    <measurement group_id="O2" value="3.15" lower_limit="0.85" upper_limit="5.46"/>
                    <measurement group_id="O3" value="2.88" lower_limit="0.5" upper_limit="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 7 (n=239, 241, 240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" lower_limit="-0.05" upper_limit="4.62"/>
                    <measurement group_id="O2" value="3.14" lower_limit="0.81" upper_limit="5.47"/>
                    <measurement group_id="O3" value="2.94" lower_limit="0.54" upper_limit="5.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 8 (n=223, 220, 222)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" lower_limit="-0.69" upper_limit="4.02"/>
                    <measurement group_id="O2" value="2.26" lower_limit="-0.09" upper_limit="4.61"/>
                    <measurement group_id="O3" value="1.49" lower_limit="-0.92" upper_limit="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 9 (n=174, 192, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" lower_limit="-0.67" upper_limit="4.18"/>
                    <measurement group_id="O2" value="2.15" lower_limit="-0.24" upper_limit="4.53"/>
                    <measurement group_id="O3" value="1.73" lower_limit="-0.73" upper_limit="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 10 (n=148, 163, 163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" lower_limit="-0.96" upper_limit="4"/>
                    <measurement group_id="O2" value="1.56" lower_limit="-0.88" upper_limit="3.99"/>
                    <measurement group_id="O3" value="1.62" lower_limit="-0.89" upper_limit="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 11 (n=99, 115, 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="-2.29" upper_limit="3"/>
                    <measurement group_id="O2" value="2.72" lower_limit="0.15" upper_limit="5.3"/>
                    <measurement group_id="O3" value="2.19" lower_limit="-0.46" upper_limit="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 12 (n=82, 97, 98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="-1.7" upper_limit="3.79"/>
                    <measurement group_id="O2" value="3.08" lower_limit="0.43" upper_limit="5.73"/>
                    <measurement group_id="O3" value="0.75" lower_limit="-1.95" upper_limit="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 13 (n=57, 85, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" lower_limit="-0.85" upper_limit="5.11"/>
                    <measurement group_id="O2" value="1.78" lower_limit="-0.94" upper_limit="4.5"/>
                    <measurement group_id="O3" value="0.82" lower_limit="-1.98" upper_limit="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 14 (n=54, 78, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" lower_limit="-3.15" upper_limit="2.89"/>
                    <measurement group_id="O2" value="1.59" lower_limit="-1.18" upper_limit="4.36"/>
                    <measurement group_id="O3" value="-0.07" lower_limit="-2.95" upper_limit="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 15 (n=44, 71, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-5.29" upper_limit="1.09"/>
                    <measurement group_id="O2" value="1.29" lower_limit="-1.53" upper_limit="4.11"/>
                    <measurement group_id="O3" value="1.49" lower_limit="-1.47" upper_limit="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Cycle 16 (n=42, 58, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" lower_limit="-5.49" upper_limit="0.97"/>
                    <measurement group_id="O2" value="1.23" lower_limit="-1.73" upper_limit="4.19"/>
                    <measurement group_id="O3" value="1.44" lower_limit="-1.59" upper_limit="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up 1 (n=173, 183, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" lower_limit="-3.38" upper_limit="1.47"/>
                    <measurement group_id="O2" value="-1.26" lower_limit="-3.66" upper_limit="1.14"/>
                    <measurement group_id="O3" value="-1.62" lower_limit="-4.11" upper_limit="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up 2 (n=143, 127, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" lower_limit="-2.56" upper_limit="2.42"/>
                    <measurement group_id="O2" value="-1.12" lower_limit="-3.65" upper_limit="1.41"/>
                    <measurement group_id="O3" value="-1.05" lower_limit="-3.62" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up 3 (n=109, 101, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" lower_limit="-2.92" upper_limit="2.28"/>
                    <measurement group_id="O2" value="-1.67" lower_limit="-4.29" upper_limit="0.96"/>
                    <measurement group_id="O3" value="-1.98" lower_limit="-4.68" upper_limit="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up 4 (n=87, 71, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" lower_limit="-3.62" upper_limit="1.8"/>
                    <measurement group_id="O2" value="-2.54" lower_limit="-5.36" upper_limit="0.29"/>
                    <measurement group_id="O3" value="-1.03" lower_limit="-3.84" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up 5 (n=70, 62, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.15" lower_limit="-4.99" upper_limit="0.69"/>
                    <measurement group_id="O2" value="-5.36" lower_limit="-8.27" upper_limit="-2.44"/>
                    <measurement group_id="O3" value="-0.82" lower_limit="-3.67" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up 6 (n=58, 45, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.77" lower_limit="-4.75" upper_limit="1.2"/>
                    <measurement group_id="O2" value="-5.32" lower_limit="-8.49" upper_limit="-2.16"/>
                    <measurement group_id="O3" value="-2.76" lower_limit="-5.82" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (up to 51 months) regardless of seriousness or relationship to investigational product</time_frame>
      <desc>Reported AEs are treatment-emergent adverse events that is AEs that developed/worsened during the ‘on treatment period’ (time from first dose of study drug until 30 days after the last administration of study drug). Analysis was performed on safety population, which was randomized participants who received study drug and analyzed according to the treatment actually received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel 75 mg/m^2</title>
          <description>Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.</description>
        </group>
        <group group_id="E2">
          <title>Cabazitaxel 20 mg/m^2</title>
          <description>Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.</description>
        </group>
        <group group_id="E3">
          <title>Cabazitaxel 25 mg/m^2</title>
          <description>Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="187" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Necrotising colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Device issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Staphylococcal osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Recall phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Wrong drug administered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of Vater</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Sebaceous carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Urinary tract neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cystitis glandularis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Urethritis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Urinary bladder rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="353" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="323" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="353" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="190" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incorrect dose administered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="387"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="369"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

